CA2677842C - Pharmaceutical composition comprising microparticle oily suspension - Google Patents

Pharmaceutical composition comprising microparticle oily suspension Download PDF

Info

Publication number
CA2677842C
CA2677842C CA2677842A CA2677842A CA2677842C CA 2677842 C CA2677842 C CA 2677842C CA 2677842 A CA2677842 A CA 2677842A CA 2677842 A CA2677842 A CA 2677842A CA 2677842 C CA2677842 C CA 2677842C
Authority
CA
Canada
Prior art keywords
active ingredient
medicinally
pharmaceutical composition
particle diameter
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2677842A
Other languages
English (en)
French (fr)
Other versions
CA2677842A1 (en
Inventor
Yasunori Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Publication of CA2677842A1 publication Critical patent/CA2677842A1/en
Application granted granted Critical
Publication of CA2677842C publication Critical patent/CA2677842C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2677842A 2007-02-16 2008-02-15 Pharmaceutical composition comprising microparticle oily suspension Active CA2677842C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007-035916 2007-02-16
JP2007035916 2007-02-16
PCT/JP2008/000230 WO2008099615A1 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物

Publications (2)

Publication Number Publication Date
CA2677842A1 CA2677842A1 (en) 2008-08-21
CA2677842C true CA2677842C (en) 2014-09-16

Family

ID=39689861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2677842A Active CA2677842C (en) 2007-02-16 2008-02-15 Pharmaceutical composition comprising microparticle oily suspension

Country Status (9)

Country Link
US (1) US8309138B2 (enExample)
EP (1) EP2123255B1 (enExample)
JP (2) JP4588791B2 (enExample)
KR (1) KR101434706B1 (enExample)
CN (1) CN101610754A (enExample)
AU (1) AU2008215659B2 (enExample)
CA (1) CA2677842C (enExample)
ES (1) ES2423929T3 (enExample)
WO (1) WO2008099615A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
US11576914B2 (en) 2017-07-26 2023-02-14 The Doshisha Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof
US12703689B2 (en) 2017-08-17 2026-08-11 University Of Delaware Furan based compositions and methods of making thereof
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004893A1 (en) 1990-09-13 1992-04-02 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー．ディー．サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
RU2186562C2 (ru) 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
NZ501112A (en) 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
KR20010040646A (ko) 1998-02-09 2001-05-15 블로닉, 조엘 위장관의 만성 염증성 질환의 치료방법
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
JP2002533378A (ja) * 1998-12-23 2002-10-08 アムジエン・インコーポレーテツド タンパク質の徐放用ポリオール／油懸濁液
KR100711538B1 (ko) 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 아미노피라졸 유도체
EP1058539A1 (en) * 1999-01-06 2000-12-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
SK286371B6 (sk) 1999-02-23 2008-08-05 Merck & Co., Inc. Farmaceutický prostriedok
IL146105A (en) 1999-04-23 2005-09-25 Tadeda Pharmaceutical Company 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor
DE60016617T2 (de) 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
IN192188B (enExample) 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
ES2225600T3 (es) * 2000-09-22 2005-03-16 Galephar M/F Composicion semi-solida de isotretinoina.
US20030157172A1 (en) 2001-12-20 2003-08-21 Lu Guang Wei Pharmaceutical suspension for oral administration
EP1490025B1 (en) 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003255844A1 (en) 2002-08-23 2004-03-11 Ionix Pharmaceuticals Limited Five-membered heterocyclic compounds in the treatment of chronic and acute pain
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US20040132755A1 (en) 2002-09-06 2004-07-08 Mark Ledeboer Isoxazoles and uses thereof
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
CA2515939A1 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
WO2004073692A1 (ja) 2003-02-18 2004-09-02 Yamashita, Shinji 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
US20060151899A1 (en) 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
JP5096658B2 (ja) 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
CN1926139A (zh) 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
ES2392344T3 (es) * 2004-05-04 2012-12-07 Hormos Medical Ltd. Formulaciones orales líquidas de ospemifeno
ATE538118T1 (de) 2004-12-28 2012-01-15 Aska Pharm Co Ltd Pyrimidinylisoxazolderivat
JP2007039408A (ja) * 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Also Published As

Publication number Publication date
WO2008099615A1 (ja) 2008-08-21
ES2423929T3 (es) 2013-09-25
US20100092565A1 (en) 2010-04-15
JP2010120974A (ja) 2010-06-03
EP2123255A4 (en) 2010-06-02
JPWO2008099615A1 (ja) 2010-05-27
CN101610754A (zh) 2009-12-23
EP2123255B1 (en) 2013-05-15
JP4588791B2 (ja) 2010-12-01
US8309138B2 (en) 2012-11-13
AU2008215659A1 (en) 2008-08-21
KR20090117894A (ko) 2009-11-13
AU2008215659B2 (en) 2012-11-01
KR101434706B1 (ko) 2014-08-26
CA2677842A1 (en) 2008-08-21
EP2123255A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
AU2008215659B2 (en) Pharmaceutical composition comprising microparticle oily suspension
EP1007030B3 (fr) Composition pharmaceutique solide contenant des derives de benzofuranne
CA2903440C (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
KR20040099298A (ko) ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
EP2018158A1 (fr) Nouvelle forme d'administration du racecadotril
JP2011157390A (ja) 胃液において不溶性の微小顆粒、その調製方法、および薬学的調製物
AU2013235167A1 (en) Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof
EP0981340A1 (fr) Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique
TWI597063B (zh) 藥物組成物及其製備方法
JP2007504190A (ja) ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンズイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−エチルプロピオネート及びそれらの塩の新規経口投与形態
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
KR100980749B1 (ko) 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물
JP2022069437A (ja) 医薬製剤およびその製造方法
CA3187241A1 (en) Pharmaceutical compositions comprising ribociclib
KR20040091133A (ko) 나노입자 형태로2-(4-에톡시-페닐)-3-(4-메탄설포닐-페닐)-피라졸로'1,5-바이피리다진을 포함하는 약제 조성물
JP2024534013A (ja) 多汗症を治療するための医薬組成物および方法
HK1070840B (en) Pharmaceutical compositions based on azetidine derivatives
HK1070840A1 (zh) 含有氮雜環丁烷衍生物的藥物組合物

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250203

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260330